Open AccessDolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV
Author(s) -
Charlotte-Paige Rolle,
Mezgebe Berhe,
Tulika Singh,
Roberto Ortiz,
Anson K Wurapa,
Moti Ramgopal,
Peter A. Leone,
James L. Matthews,
Marybeth Dalessandro,
Mark Underwood,
Konstantinos Angelis,
Brian Wynne,
Deanna Merrill,
Christopher Nguyen,
Jean van Wyk,
Andrew Zolopa
Publication year - 2021
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000002979
Subject(s) - dolutegravir , lamivudine , medicine , adverse effect , regimen , rash , resistance mutation , viral load , hepatitis b virus , human immunodeficiency virus (hiv) , immunology , virus , antiretroviral therapy , reverse transcriptase , rna , biochemistry , chemistry , gene
Dolutegravir/lamivudine (DTG/3TC) is indicated for treatment-naive and experienced people with HIV; however, questions remain about its utility in a test-and-treat setting because of potential transmitted resistance and baseline hepatitis B virus (HBV) co-infection. We present feasibility and efficacy of DTG/3TC in newly diagnosed individuals in a test-and-treat setting.